Eli Lilly's Q3 2023 Results Beat Estimates, but GLP-1 Growth Potential Limited

Deutsche Bank's James Shin initiated their coverage on Eli Lilly & Co (NYSE: LLY) with a Hold rating and a $535 price target.

In their analysis, Shin highlighted the company's strong performance in the third quarter of 2023, with revenues of $9.5 billion, beating the Zacks Consensus Estimate of $8.88 billion. However, despite the positive earnings report, Shin expressed concerns about Eli Lilly's profit multiple, which currently stands at a "all-time high" of 48x. This valuation is attributed to the success of the GLP-1 phenomenon, a drug class used in the treatment of diabesity. While the GLP-1 market presents significant growth potential, Shin cautioned that the early stages of commercialization could be disrupted by looming competitors.

Shin's coverage also compared Eli Lilly to its peer, Novo Nordisk, suggesting that the former should be valued higher. However, the analyst's overall rating remained at Hold due to the uncertainties surrounding the commercialization of GLP-1.

Eli Lilly's management provided guidance for FY 2023, forecasting an EPS range of $6.50 to $6.70 and revenue between $33.4 billion and $33.9 billion. The company also highlighted its focus on growth and delivering innovative medicines to improve the lives of patients worldwide.

Analysts' consensus forecast for Eli Lilly's upcoming year projects an EPS of $8.01, representing a year-over-year increase of 44.7%. This optimistic outlook indicates potential growth for the company.

Since the release of Eli Lilly's Q3 2023 earnings report on November 2, the stock price has risen by 6.7%. Over the past year, the stock has experienced significant growth, with a 68.9% increase. During this period, Eli Lilly has outperformed the S&P 500, which has seen a 13.6% increase.

It's worth noting that James Shin, the Deutsche Bank analyst who initiated coverage on Eli Lilly, is ranked in the bottom 26% of Wall Street analysts by WallStreetZen. With an average return of -14.8% and a win rate of 0%, Shin's track record may raise some concerns among investors. However, it is important to evaluate the analysis independently and consider other sources before making investment decisions.

Eli Lilly and Company, founded in 1876 and headquartered in Indianapolis, IN, is a pharmaceutical company that offers a wide range of medicines for various medical conditions, including cardiovascular diseases, diabetes, cancer, neurological disorders, immune disorders, men's health, and musculoskeletal problems.

Want to get in touch? Email us at news@wallstreetzen.com.

WallStreetZen and Don Francis do not hold any positions in the companies mentioned in this article. The information and statistics provided herein are presented for general informational purposes only and may not be accurate, complete, or up-to-date. It should not be interpreted as a recommendation to buy or sell any stocks and should not be solely relied upon for making investment decisions. It does not take into account your financial situation or risk profile. All investors should conduct their own investment due diligence before buying a stock. WallStreetZen expressly disclaims any liability for the accuracy, reliability, or completeness of the analysts' information, price targets, ratings, or opinions.